SIR Capital Management L.P. Acquires Shares of 16,400 Ralliant Corporation $RAL

Key Points

• SIR Capital Management acquired 16,400 Ralliant shares worth approximately $1.21 million during the second quarter, while several other institutional investors also initiated or increased positions.
• Ralliant reported quarterly EPS of $0.68, beating expectations of $0.63, on revenue of $567.8 million. The company issued fiscal 2026 EPS guidance of $2.76–$2.90 and expects third-quarter EPS of $0.72–$0.78.
• Analyst sentiment is generally positive, with a consensus “Moderate Buy” rating and an average price target of $75.70. However, company insiders sold shares under pre-arranged trading plans, and Ralliant announced a quarterly dividend of $0.05 per share.

SIR Capital Management L.P. acquired a new position in shares of Ralliant Corporation (NYSE:RAL - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 16,400 shares of the company's stock, valued at approximately $1,208,000.

Several other large investors have also modified their holdings of the business. Danske Bank A S bought a new position in Ralliant in the fourth quarter worth about $25,000. Dunhill Financial LLC acquired a new stake in shares of Ralliant during the second quarter worth $25,000. Allworth Financial LP increased its holdings in shares of Ralliant by 134.4% in the fourth quarter. Allworth Financial LP now owns 511 shares of the company's stock valued at $26,000 after purchasing an additional 293 shares during the period. Palisade Asset Management LLC purchased a new stake in Ralliant in the third quarter valued at approximately $26,000. Finally, BOKF NA purchased a new stake in shares of Ralliant in the 3rd quarter valued at $29,000.

Insider Activity

In related news, CEO Tamara S. Newcombe sold 12,936 shares of the business's stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $71.79, for a total transaction of $928,675.44. Following the completion of the sale, the chief executive officer owned 251,967 shares in the company, valued at $18,088,710.93. The trade was a 4.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karen M. Bick sold 6,062 shares of the firm's stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $72.00, for a total transaction of $436,464.00. Following the sale, the senior vice president directly owned 31,668 shares in the company, valued at approximately $2,280,096. The trade was a 16.07% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.42% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Ralliant in a report on Friday, July 31st. Royal Bank Of Canada upped their price target on shares of Ralliant from $71.00 to $73.00 and gave the stock a "sector perform" rating in a research report on Friday, July 31st. Morgan Stanley raised their price objective on Ralliant from $68.00 to $85.00 and gave the company an "overweight" rating in a report on Tuesday, June 23rd. Oppenheimer raised their target price on shares of Ralliant from $50.00 to $65.00 and gave the stock an "outperform" rating in a research note on Wednesday, May 13th. Finally, BMO Capital Markets began coverage on shares of Ralliant in a research report on Monday, July 20th. They set a "market perform" rating and a $78.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Ralliant has a consensus rating of "Moderate Buy" and an average price target of $75.70.

Ralliant Stock Performance

NYSE:RAL opened at $62.84 on Tuesday. Ralliant Corporation has a 52 week low of $37.27 and a 52 week high of $75.41. The company has a market cap of $6.95 billion, a price-to-earnings ratio of -5.79, a price-to-earnings-growth ratio of 2.36 and a beta of 1.61. The company has a quick ratio of 1.00, a current ratio of 1.52 and a debt-to-equity ratio of 0.75. The company has a fifty day simple moving average of $68.83 and a two-hundred day simple moving average of $56.00.

Ralliant (NYSE:RAL - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.68 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.63 by $0.05. The company had revenue of $567.80 million for the quarter. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. As a group, equities analysts anticipate that Ralliant Corporation will post 2.87 earnings per share for the current fiscal year.

Ralliant Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Investors of record on Tuesday, September 8th will be issued a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 8th. Ralliant's dividend payout ratio is -1.84%.

About Ralliant

Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

Want to see what other hedge funds are holding RAL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ralliant Corporation (NYSE:RAL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source